

The Cancer Drugs Fund

David Thomson,
Lead Pharmacist



Yorkshire Cancer Network

Number of approved CDF applications by treatment (1 Apr 2011 – 20 Dec 2011)

| Drug Name | Total approved |
|--|----------------|
| Avastin (bevacizumab) | 2,110 |
| Erlotinib (erlotinib) | 807 |
| Tyverb (lapatinib) | 406 |
| Zytiga (abiraterone) | 400 |
| Afinitor (everolimus) | 474 |
| MabThera (rituximab) | 426 |
| Nexavar (sorafenib) | 377 |
| Levact (bendamustine) | 312 |
| Faslodex (fulvestrant) | 222 |
| Velcade (bortezomib) | 144 |
| Halaven (eribulin) | 143 |
| Vidaza (azacitidine) | 127 |
| Tarceva (erlotinib) | 100 |
| Jevtana (cabazitaxel) | 90 |
| Other | 92 |
| Sutent (sunitinib) | 77 |
| Revlimid (lenalidomide) | 62 |
| Tasigna (nilotinib) | 52 |
| Sprycel (dasatinib) | 51 |
| Torisei (temsirolimus) | 51 |
| MabCampath (alemtuzumab) | 49 |
| Glivec (imatinib) | 47 |
| Yervoy (ipilimumab) | 45 |
| Victoix (panitumumab) | 43 |
| Alimta (pemetrexed) | 42 |
| Paclitaxel (abraxane) | 30 |
| Votrient (pazopanib) | 36 |
| Caelyx or Myocet (liposomal doxorubicin) | 26 |
| Arzerra (ofatumumab) | 25 |
| Evotra (clofarabine) | 22 |
| Javlor (vinflunine) | 21 |
| Folfox | 21 |
| lyttrium | 19 |
| Herceptin (trastuzumab) | 14 |
| Total | 7,146 |



Yorkshire Cancer Network

Rarer Cancers Foundation, *The Cancer Drugs Fund (CDF) – An overview of progress so far*, 03 January 2012.

..... but the CDF has also created many headlines.



Yorkshire Cancer Network

Fears of postcode lottery in £200m Cancer Drugs Fund

A £200million a year fund to buy much-needed treatment for cancer sufferers is launched today but campaigners fear it could lead to a postcode lottery in care.

The Telegraph, 1st April 2011. <http://www.telegraph.co.uk/health/healthnews/8419354/Fears-of-postcode-lottery-in-200m-Cancer-Drugs-Fund.html>



Yorkshire Cancer Network

Are CDF lists really that different?

- Yes – if you simply look at the different SHA lists.
- However many factors may help account for the differences:
 - Some drugs will be in baseline commissioning in some areas and therefore not on lists.
 - No requests received for drugs to be added to cohort lists
 - **Clinical** opinions differ on whether some new medicines should be offered and/ or at what line of treatment



Yorkshire Cancer Network

Cancer fund betrayal: It promised £200m for vital drugs, but millions haven't been spent - and patients are paying the price

Patients being turned down in underspent regions - with some funding their own drugs

The Daily Mail, 26th December 2011: <http://www.dailymail.co.uk/health/article-2078575/Cancer-Drugs-Fund-Millions-havent-spent-patients-paying-price.html#ixzz1X1zw1k2o>



Yorkshire Cancer Network

Yorkshire and Humber SHA Financial Summary

| Fund Summary FY 2011/12 | | £'000 |
|--------------------------------|--|--------|
| Total Fund 2011/12 | | 14,137 |
| Total Committed/Agreed 2011/12 | | 8,423 |
| Total Variance 2011/12 | | 5,714 |

| Fund Summary FY 2010/11 | | £'000 |
|--------------------------------|--|-------|
| Total Fund FY 2010/11 | | 5,247 |
| Total Committed/Agreed 2010/11 | | 965 |
| Total Variance FY 2010/11 | | 4,282 |



Yorkshire Cancer Network

Take-up of the Cancer Drugs Fund

“...panels are tasked with making very difficult decisions on future commitments. By approving a drug for a patient the panel is potentially committing funds from next year’s allocation of the Fund as well as the current year’s allocation.”

Macmillan Cancer Support. *Improving Access? Report on the implementation of the Cancer Drugs Fund and the development of a value-based pricing system. December 2011*



Yorkshire Cancer Network

Example drug - Costalotamumab

- Estimated cost per patient, per 8 month course = £19,200
- Estimated 170 eligible patients per annum
= **Estimated per annum cost of £3,264,000**

| | Oct 11 | Nov 11 | Dec 11 | Jan 12 | Feb 12 | Mar 12 | | | | | |
|-----------------|---------|---------|----------|----------|----------|----------|--|--|--|--|--|
| No. of patients | 14 | 28 | 42 | 56 | 70 | 84 | | | | | |
| Cost | £33,600 | £67,200 | £100,800 | £134,400 | £168,000 | £201,600 | | | | | |

- In year 1 we only spend £705,600
 - Or commit spend on 84 patients (£1,612,800)



Yorkshire Cancer Network

Yorkshire and Humber SHA Financial Summary

| Fund Summary FY 2011/12 | | £'000 |
|--------------------------------|--|--------|
| Total Fund 2011/12 | | 14,137 |
| Total Committed/Agreed 2011/12 | | 8,423 |
| Total Variance 2011/12 | | 5,714 |
| Total Committed/Agreed 2012/13 | | 4,127 |
| Total Committed/Agreed | | 12,550 |
| Total Variance / Remaining | | 1,588 |

| Fund Summary FY 2010/11 | | £'000 |
|-----------------------------------|--|-------|
| Total Fund FY 2010/11 | | 5,247 |
| Total Committed/Agreed 2010/11 | | 965 |
| Total Variance FY 2010/11 | | 4,282 |
| Total Committed/Agreed in 2011/12 | | 1,650 |
| Total Committed/Agreed in 2012/13 | | 318 |
| Total Committed/Agreed | | 2,933 |
| Total Variance / Remaining | | 2,314 |



Yorkshire Cancer Network

Example drug - Costalotamumab

- Estimated cost per patient, per 8 month course = £19,200
- Estimated 170 eligible patients per annum
= **Estimated per annum cost of £3,264,000**

| | Oct 11 | Nov 11 | Dec 11 | Jan 12 | Feb 12 | Mar 12 | Apr 12 | May 12 | Jun 12 | Jul 12 | Aug 12 |
|-----------------|---------|---------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| No. of patients | 14 | 28 | 42 | 56 | 70 | 84 | 98 | 112 | 112 | 112 | 112 |
| Cost | £33,600 | £67,200 | £100,800 | £134,400 | £168,000 | £201,600 | £235,200 | £268,800 | £268,800 | £268,800 | £268,800 |

- In year 1 we only spend £705,600
 - Or commit spend on 84 patients (£1,612,800)
- In year 2 we would spend £2,923,200
 - Or commit spend on 170 patients (£3,264,000)



Yorkshire Cancer Network

Estimated spend in 2012/13 on drugs approved in 2010/12

| Fund Summary FY 2012/13 | £'000 |
|----------------------------------|--------|
| Total Fund 2012/13 | 20,000 |
| Estimated pre-commitment 2012/13 | 19,956 |

- Based on the estimated commitment in 2012/13 for the drugs already approved in 2010/12
- Does not include new drugs available in 2012/13



Yorkshire Cancer Network

What is the impact of the CDF on Cancer Outcomes?



Yorkshire Cancer Network

Rarer Cancers Foundation

| | RCF Number of patients ^{1,2} | RCF Total Expenditure ^{1,2,c} |
|-----------------|---------------------------------------|--|
| Present usage | 2,200 ^a | £45,806,200 |
| Usage in year 1 | 4,840 ^b | £100,773,640 |
| Usage in year 2 | 7,163 ^b | £149,144,987 |
| Usage in year 3 | 10,602 ^b | £220,734,581 |

RCF Assumptions

- 2,200 approved exceptional case applications per annum.
- Increase in demand in 1st year after a positive NICE recommendation is 120%; Increase in demand in 2nd and 3rd years after a positive NICE recommendation is 48%.
- Average cost of an unfunded cancer treatment £20,821 per patient** (nb. Includes cost of admin and medical management, ?VAT)



Yorkshire Cancer Network

1. Rarer Cancers Foundation, *Exceptional England?: An investigation of the role of Primary Care Trusts in making cancer medicines available through exceptional case processes*, 23 October 2008.

2. Rarer Cancers Foundation, *Exceptional funding: Recommendations for improving access to cancer medicines and delivering better value for money for the NHS*, August 2010.

Estimate using same methodology but based on experience so far....

| | RCF Number of patients | RCF Total Expenditure | Estimated No of patients | Estimated total expenditure ^d |
|-----------------|------------------------|-----------------------|--------------------------|--|
| Present usage | 2,200 | £45,806,200 | 2,837 ^a | |
| Usage in year 1 | 4,840 | £100,773,640 | | |
| Usage in year 2 | 7,163 | £149,144,987 | | |
| Usage in year 3 | 10,602 | £220,734,581 | | |

Assumptions

- a) Actual number of approvals between Oct10 – Mar11¹.

1. Hansard, Commons Debates, 18 Apr 2012 :Column 415W.

<http://www.publications.parliament.uk/pa/cm201212/cmhansrd/cm120418/text/120418w0003.htm> Accessed 12th June 2012



Yorkshire Cancer Network
Accessed 12th June 2012

Estimate using same methodology but based on experience so far....

| | RCF Number of patients | RCF Total Expenditure | Estimated No of patients | Estimated total expenditure ^d |
|-----------------|------------------------|-----------------------|--------------------------|--|
| Present usage | 2,200 | £45,806,200 | 2,837 ^a | |
| Usage in year 1 | 4,840 | £100,773,640 | 10,799 ^b | |
| Usage in year 2 | 7,163 | £149,144,987 | | |
| Usage in year 3 | 10,602 | £220,734,581 | | |

Assumptions

- a) Actual number of approvals between Oct10 – Mar11¹.
b) 9,899 treatments made available between Apr11 – Feb12¹; total number of patients treated in 2011/12 by extrapolating this figure is 10,799.

1. Hansard, Commons Debates, 18 Apr 2012 :Column 415W.

<http://www.publications.parliament.uk/pa/cm201212/cmhansrd/cm120418/text/120418w0003.htm> Accessed 12th June 2012



Yorkshire Cancer Network
Accessed 12th June 2012

Estimate using same methodology but based on experience so far....

| | RCF Number of patients | RCF Total Expenditure | Estimated No of patients | Estimated total expenditure ^d |
|-----------------|------------------------|-----------------------|--------------------------|--|
| Present usage | 2,200 | £45,806,200 | 2,837 ^a | |
| Usage in year 1 | 4,840 | £100,773,640 | 10,799 ^b | |
| Usage in year 2 | 7,163 | £149,144,987 | 15,983 ^c | |
| Usage in year 3 | 10,602 | £220,734,581 | 23,655 ^c | |

Assumptions

- a) Actual number of approvals between Oct10 – Mar11¹.
- b) 9,899 treatments made available between Apr11 – Feb12¹; total number of patients treated in 2011/12 by extrapolating this figure is 10,799.
- c) Applying same factor (1.48) as in column 2 year on year



1. Hansard, Commons Debates, 18 Apr 2012 :Column 415W.

<http://www.publications.parliament.uk/pa/cm201212/cmhansrd/cm120418/text/120418w0003.htm> Accessed 12th June 2012

Yorkshire Cancer Network
Accessed 12th June 2012

Estimate using same methodology but based on experience so far....

| | RCF Number of patients | RCF Total Expenditure | Estimated No of patients | Estimated total expenditure ^d |
|-----------------|------------------------|-----------------------|--------------------------|--|
| Present usage | 2,200 | £45,806,200 | 2,837 ^a | £59,069,177 |
| Usage in year 1 | 4,840 | £100,773,640 | 10,799 ^b | £224,845,979 |
| Usage in year 2 | 7,163 | £149,144,987 | 15,983 ^c | £332,782,043 |
| Usage in year 3 | 10,602 | £220,734,581 | 23,655 ^c | £492,520,755 |

Assumptions

- a) Actual number of approvals between Oct10 – Mar11¹.
- b) 9,899 treatments made available between Apr11 – Feb12¹; total number of patients treated in 2011/12 by extrapolating this figure is 10,799.
- c) Applying same factor (1.48) as in column 2 year on year
- d) Average cost of an unfunded cancer treatment £20,821 per patient



1. Hansard, Commons Debates, 18 Apr 2012 :Column 415W.

<http://www.publications.parliament.uk/pa/cm201212/cmhansrd/cm120418/text/120418w0003.htm> Accessed 12th June 2012

Yorkshire Cancer Network
Accessed 12th June 2012

Double the patient numbers but one third the expected expenditure !?!

| | RCF Number of patients | RCF Total Expenditure | Actual No of patients ¹ | Estimated total expenditure | Actual expenditure ¹ |
|-----------------|------------------------|-----------------------|------------------------------------|-----------------------------|---------------------------------|
| Oct 10 – Mar 11 | 2,200 | £45,806,200 | 2,837 | £59,069,177 | £38,254,000 |
| Apr 11 – Mar 12 | 4,840 | £100,773,640 | 10,799 | £224,845,979 | £80,529,000 |

1. Hansard, Commons Debates, 18 Apr 2012 :Column 415W.

<http://www.publications.parliament.uk/pa/cm201212/cmhansrd/cm120418/text/120418w0003.htm> Accessed 12th June 2012



Yorkshire Cancer Network

Possible reasons?

“.....but we're starting to realise that the way these drugs are used in normal practice is rather different from how they're used in the setting of carefully controlled clinical trials”

Professor Adrian Newland; Chair, London New Cancer Drugs Group. 21st March 2012.

<http://info.cancerresearchuk.org/news/archive/cancernews/2012-03-21-Analysis-reveals-most-common-Cancer-Drugs-Fund-applications?rss=true> Accessed 11th June 2012



Yorkshire Cancer Network

Implications

- If reduced duration of treatment results in or is a result of poorer outcomes it may question the DH assessment of the impact of the CDF.
 - Need to better understand the reasons for the differences and the effects on outcomes.
 - National CDF audit/ SACT Dataset very important.



Yorkshire Cancer Network

Real world oncology evidence and VBP – A unique opportunity for an integrated NHS solution?

SACT Systemic Anti-Cancer Therapy
Chemotherapy Dataset

ciu
Chemotherapy Intelligence Unit



Yorkshire Cancer Network

Thank you for your attention

Questions?



Yorkshire Cancer Network